EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Biovigilance in Faecal Microbiota Transplantation: 7‐Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events

Biovigilanz bei fäkaler Mikrobiota-Transplantation: 7-Jahres-Kohortenstudie und Rahmen für mikrobiologische Bewertungen infektiöser unerwünschter Ereignisse

V O Chernova iD, J van Prehn, B Groenewegen, E van Lingen, E J Kuijper, M M C Lambregts, E van Nood, G Choi, M D Hazenberg, J J Keller, E M Terveer

United European Gastroenterology Journal · 2026-06 · 14 (5)

DOI: 10.1002/ueg2.70239 ↗

Auf einen Blick

In dieser Kohortenstudie waren donorbezogene Infektionen nach FMT selten, traten aber auf. Insgesamt blieb die Sicherheit günstig, besonders bei rCDI; bei Nicht-CDI-Patient:innen war das Risiko höher.

Fragestellung

Wie häufig traten infektiöse Komplikationen nach FMT auf, und wie sollte eine strukturierte Biovigilanz dafür aussehen?

Methode

Prospektive Beobachtungskohortenstudie aller Patient:innen mit gefrorenen Donor-Stuhl-Suspensionen der NDFB von May 2016–December 2023; Erfassung von (S)AEs nach 3 weeks, 3 months und 6 months.

Ergebnisse

290 rCDI-Patient:innen (322 FMTs) und 35 EAP-Patient:innen (75 FMTs). SARs nach 6 of 322 FMTs (1,9 %) in rCDI und 3 of 75 FMTs (4,0 %) in EAP; 2 donor-derived E. coli-Infektionen wurden bestätigt.

Einschränkungen

Keine Angabe zu randomisiertem Design oder Kontrollgruppe; der vorgeschlagene Biovigilanz-Ansatz wurde nicht als Implementierungsstudie geprüft.

Schlussfolgerung der Autor:innen

Donor-derived infections were rare but present, particularly in non-CDI patients with substantial comorbidity, whereas overall safety remained favourable. A SoHO-compliant biovigilance protocol is essential.

Kernaussagen

  • SARs nach 6 of 322 FMTs in rCDI und 3 of 75 FMTs in EAP
  • 2 donor-derived E. coli-Infektionen bei EAP-Patient:innen
  • Biovigilanz mit Mikrobiologie und Traceability wird als wesentlich beschrieben

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 12.06.2026. Verfasst von V O Chernova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Netherlands Donor Feces Bank, Leiden University Center of Infectious Diseases- Medical Microbiology & Infection Prevention (LUCID-MMIP), Leiden Unive…. Hauptthemen laut MEDLINE: Clostridium Infections, Fecal Microbiota Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Faecal microbiota transplantation (FMT) is increasingly used. However, no systematic approach exists to assess infectious risks after FMT, leading to underreporting. We evaluated infectious complications at the Netherlands Donor Feces Bank (NDFB) and proposed a structured biovigilance approach aligned with the EU Regulation on Substances of Human Origin (SoHO).

Methods

We conducted a prospective observational cohort study of all patients receiving frozen donor faecal suspensions from the NDFB (May 2016–December 2023) for recurrent Clostridioides difficile infection (rCDI) or via an extended access programme (EAP) for non‐CDI indications. (Serious) adverse events ((S)AEs) were reported by physicians and recorded at 3 weeks, 3 months, and 6 months. Serious adverse reactions (SARs) were defined as SAEs probably or definitely related to FMT.

Results

We included 290 rCDI patients (322 FMTs) and 35 EAP patients (75 FMTs). FMT efficacy was favourable overall: 92% of rCDI patients remained free of rCDI within 8 weeks, and 49% of EAP patients achieved at least a partial response. Sixty‐one per cent of rCDI patients and 34% of EAP patients had mild gastrointestinal AEs. AE incidences were comparable across groups (rCDI: 5.1 vs. EAP: 4.4 per 100 patient–weeks). SAEs were more frequent in EAP patients (0.66 vs. 0.28 per patient), reflecting higher immunosuppression and comorbidity. FMT‐attributable SARs occurred after 6 of 322 FMTs (1.9%) in the rCDI group and after 3 of 75 FMTs (4.0%) in the EAP group. Two donor–derived Escherichia coli infections in EAP patients with predisposing conditions were confirmed, consistent with early donor–strain colonisation rather than a direct FMT effect. Most SAEs were unrelated.

Conclusions

In this 7‐year cohort, donor‐derived infections were rare but present, particularly in non‐CDI patients with substantial comorbidity, whereas overall safety remained favourable. A SoHO‐compliant biovigilance protocol incorporating microbiological investigation and donor/sample traceability is essential for the safe clinical use of FMT and faecal microbiota products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridium InfectionsFecal Microbiota TransplantationAdultAgedFemaleHumansMaleMiddle AgedClostridioides difficileNetherlandsProspective StudiesRecurrenceTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

Clostridioides difficile infectionbiovigilanceextended access programmefaecal microbiota transplantationinfectious adverse events

Autor:innen und Institutionen

  • Netherlands Donor Feces Bank, Leiden University Center of Infectious Diseases- Medical Microbiology & Infection Prevention (LUCID-MMIP), Leiden University Medical Center (LUMC), Leiden, the Netherlands.
  • Department of Neurology, LUMC, Leiden, the Netherlands.
  • Center for Microbiota Analyses and Therapeutics, Leiden University Center for Infectious Diseases-Research (LUCID-R), LUMC, Leiden, the Netherlands.
  • Department of Gastroenterology and Hepatology, LUMC, Leiden, the Netherlands.
  • Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.

ORCID-Profile: V O Chernova

Zitieren

APA

Chernova, V. O., van Prehn, J., Groenewegen, B., van Lingen, E., Kuijper, E. J., Lambregts, M. M. C., van Nood, E., Choi, G., Hazenberg, M. D., Keller, J. J., & Terveer, E. M. (2026). Biovigilance in Faecal Microbiota Transplantation: 7‐Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events. United European Gastroenterology Journal, 14(5). https://doi.org/10.1002/ueg2.70239

Vancouver

Chernova VO, van Prehn J, Groenewegen B, van Lingen E, Kuijper EJ, Lambregts MMC, et al. Biovigilance in Faecal Microbiota Transplantation: 7‐Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events. United European Gastroenterology Journal. 2026;14(5). doi:10.1002/ueg2.70239

BibTeX
@article{Chernova2026,
  author = {Chernova, V O and van Prehn, J and Groenewegen, B and van Lingen, E and Kuijper, E J and Lambregts, M M C and van Nood, E and Choi, G and Hazenberg, M D and Keller, J J and Terveer, E M},
  title = {Biovigilance in Faecal Microbiota Transplantation: 7‐Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  volume = {14},
  number = {5},
  doi = {10.1002/ueg2.70239}
}
Kostenlos starten →